Memorial Sloan Kettering Cancer Center
2022 - Research.com Rising Star of Science Award
Alexander Drilon mainly investigates Cancer research, Entrectinib, Adenocarcinoma, Internal medicine and Oncology. His Cancer research research includes themes of Mutation, Gene, Mutant, Tyrosine kinase and Pathology. His Entrectinib study is within the categories of Trk receptor and Cancer.
His Adenocarcinoma research includes elements of Cabozantinib, Bioinformatics, KRAS, Lung and Lung cancer. His study on Clinical trial is often connected to Response Evaluation Criteria in Solid Tumors as part of broader study in Internal medicine. His Clinical trial study integrates concerns from other disciplines, such as Young adult and Odds ratio.
Alexander Drilon mainly focuses on Cancer research, Internal medicine, Oncology, Lung cancer and Cancer. His Cancer research research is multidisciplinary, relying on both ROS1, Trk receptor, Kinase and Targeted therapy. In Oncology, Alexander Drilon works on issues like Chemotherapy, which are connected to Immunotherapy.
His Lung cancer study incorporates themes from KRAS, Cabozantinib and Adenocarcinoma. The study incorporates disciplines such as Carcinoma and Pathology in addition to Adenocarcinoma. His Cancer research is multidisciplinary, incorporating elements of Fusion gene, Drug resistance, MAPK/ERK pathway and Confidence interval.
Cancer research, Internal medicine, Oncology, Lung cancer and Trk receptor are his primary areas of study. His Cancer research research includes elements of Tyrosine kinase, ROS1 and Receptor tyrosine kinase, Kinase. His Tyrosine kinase study integrates concerns from other disciplines, such as Mutation and Cabozantinib.
Alexander Drilon is studying Entrectinib, which is a component of Oncology. Alexander Drilon has included themes like Targeted therapy and Adenocarcinoma in his Lung cancer study. His research integrates issues of Tropomyosin receptor kinase A, Gene and Immunotherapy in his study of Trk receptor.
His primary areas of investigation include Cancer research, Internal medicine, Lung cancer, Cancer and Clinical trial. His Cancer research study combines topics in areas such as Tyrosine kinase, ROS1, Trk receptor and Gene. In his research on the topic of Internal medicine, Central nervous system is strongly related with Oncology.
The concepts of his Cancer study are interwoven with issues in Druggability and Signal transduction. His work deals with themes such as Adverse effect and Progression-free survival, which intersect with Clinical trial. The study incorporates disciplines such as Young adult and Entrectinib in addition to Adverse effect.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois.
The New England Journal of Medicine (2018)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena.
Lancet Oncology (2020)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel.
Cancer Discovery (2017)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco;Maurizio Scaltriti;Alexander Drilon.
Nature Reviews Clinical Oncology (2018)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres;A. Drilon;A. Lusque;L. Mhanna.
Annals of Oncology (2019)
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara.
Cancer Discovery (2013)
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon.
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik;Paul K. Paik;Alexander Drilon;Alexander Drilon;Pang Dian Fan;Helena Yu;Helena Yu.
Cancer Discovery (2015)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron.
Cancer Discovery (2017)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago.
Lancet Oncology (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: